{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:48:50Z","timestamp":1785728930830,"version":"3.56.0"},"reference-count":122,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic heterogeneity. Several risk factors including advanced age, previous illnesses, and a\u00a0compromised immune system contribute to an unfavorable outcome. In patients with hematologic malignancy, the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is significantly reduced explaining why the mortality rate of hematologic patients hospitalized for a SARS-CoV-2 infection is about 34%. Active immunization is an essential pillar to prevent SARS-CoV-2 infections in patients with hematologic malignancy. However, the immune response to SARS-CoV-2 vaccines may be significantly impaired, as only half of patients with hematologic malignancy develop a measurable antiviral antibody response. The subtype of hematologic malignancy and B cell\u2013depleting treatment predict a poor immune response to vaccination. Recently, antiviral drugs and monoclonal antibodies for pre-exposure or postexposure prophylaxis and for early treatment of COVID-19 have become available. These therapies should be offered to patients at high risk for severe COVID-19 and vaccine nonresponders. Importantly, as the virus evolves, some therapies may lose their clinical efficacy against new variants. Therefore, the ongoing pandemic will remain a major challenge for patients with hematologic malignancy and their caregivers who need to constantly monitor the scientific progress in this area.<\/jats:p>","DOI":"10.1182\/blood.2021012251","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T18:04:12Z","timestamp":1652292252000},"page":"236-252","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":132,"title":["COVID-19 in patients with hematologic malignancy"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6654-0304","authenticated-orcid":false,"given":"Petra","family":"Langerbeins","sequence":"first","affiliation":[{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of\u00a0Excellence, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, CECAD Cluster of\u00a0Excellence, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2022072115252901800_B1","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/infdis\/jiab082","article-title":"S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath polymerase chain reaction","volume":"223","author":"Kidd","year":"2021","journal-title":"J Infect Dis."},{"issue":"7858","key":"2022072115252901800_B2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41586-021-03470-x","article-title":"Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England","volume":"593","author":"Volz","year":"2021","journal-title":"Nature."},{"issue":"9","key":"2022072115252901800_B3","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","article-title":"Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera","volume":"184","author":"Zhou","year":"2021","journal-title":"Cell."},{"issue":"6544","key":"2022072115252901800_B4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.abh2644","article-title":"Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil","volume":"372","author":"Faria","year":"2021","journal-title":"Science."},{"issue":"10293","key":"2022072115252901800_B5","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness","volume":"397","author":"Sheikh","year":"2021","journal-title":"Lancet."},{"issue":"4","key":"2022072115252901800_B6","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jmv.27515","article-title":"Omicron variant genome evolution and phylogenetics","volume":"94","author":"Kandeel","year":"2021","journal-title":"J Med Virol."},{"issue":"6","key":"2022072115252901800_B7","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s41375-020-0836-7","article-title":"COVID-19 in persons with haematological cancers","volume":"34","author":"He","year":"2020","journal-title":"Leukemia."},{"issue":"1","key":"2022072115252901800_B8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","article-title":"COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)","volume":"14","author":"Pagano","year":"2021","journal-title":"J Hematol Oncol."},{"issue":"20","key":"2022072115252901800_B9","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1200\/JCO.21.01074","article-title":"Outcomes of COVID-19 in patients with cancer: report from the national COVID cohort collaborative (N3C)","volume":"39","author":"Sharafeldin","year":"2021","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022072115252901800_B10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.annonc.2021.02.024","article-title":"Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium","volume":"32","author":"Grivas","year":"2021","journal-title":"Ann Oncol."},{"issue":"2","key":"2022072115252901800_B11","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/jmv.26404","article-title":"The outcome of COVID-19 in patients with hematological malignancy","volume":"93","author":"Yigenoglu","year":"2021","journal-title":"J Med Virol."},{"issue":"4","key":"2022072115252901800_B12","first-page":"536","article-title":"Clinical characteristics and evolution of hematological patients and COVID-19 in Argentina: a report from the Argentine Society of Hematology","volume":"81","author":"Basquiera","year":"2021","journal-title":"Medicina (B Aires)."},{"issue":"4","key":"2022072115252901800_B13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/s41409-020-01084-x","article-title":"COVID-19 in hematopoietic cell transplant recipients","volume":"56","author":"Altuntas","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"10","key":"2022072115252901800_B14","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1038\/s41375-021-01302-5","article-title":"COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey","volume":"35","author":"Ljungman","year":"2021","journal-title":"Leukemia."},{"issue":"10","key":"2022072115252901800_B15","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol."},{"issue":"1","key":"2022072115252901800_B16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40164-020-00177-z","article-title":"Risk factors and outcome of COVID-19 in patients with hematological malignancies","volume":"9","author":"Pi\u00f1ana","year":"2020","journal-title":"Exp Hematol Oncol."},{"issue":"1","key":"2022072115252901800_B17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4274\/tjh.galenos.2021.2021.0287","article-title":"Clinical characteristics and outcome of COVID-19 in Turkish hematological malignancy patients","volume":"39","author":"Civriz Bozda\u011f","year":"2021","journal-title":"Turk J Haematol."},{"issue":"7821","key":"2022072115252901800_B18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature."},{"issue":"8","key":"2022072115252901800_B19","doi-asserted-by":"crossref","first-page":"e0255524","DOI":"10.1371\/journal.pone.0255524","article-title":"In-hospital mortality among immunosuppressed patients with COVID-19: analysis from a national cohort in Spain","volume":"16","author":"Su\u00e1rez-Garc\u00eda","year":"2021","journal-title":"PLoS One."},{"issue":"14","key":"2022072115252901800_B20","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1080\/10428194.2021.1966782","article-title":"COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome","volume":"62","author":"Levy","year":"2021","journal-title":"Leuk Lymphoma."},{"issue":"3","key":"2022072115252901800_B21","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3026(20)30429-4","article-title":"Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study","volume":"8","author":"Sharma","year":"2021","journal-title":"Lancet Haematol."},{"issue":"1","key":"2022072115252901800_B22","first-page":"1","article-title":"Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care centre in India","volume":"101","author":"Gupta","year":"2021","journal-title":"Ann Hematol."},{"issue":"10","key":"2022072115252901800_B23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S1470-2045(20)30442-3","article-title":"COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"2022072115252901800_B24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jamaoncol.2020.6178","article-title":"Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol."},{"issue":"5","key":"2022072115252901800_B25","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41416-021-01452-4","article-title":"Mortality of patients with solid and haematological cancers presenting with symptoms of COVID-19 with vs without detectable SARS-COV-2: a French nationwide prospective cohort study","volume":"125","author":"Assaad","year":"2021","journal-title":"Br J Cancer."},{"key":"2022072115252901800_B26","doi-asserted-by":"crossref","first-page":"102525","DOI":"10.1016\/j.bcmd.2020.102525","article-title":"Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies","volume":"87","author":"Borah","year":"2021","journal-title":"Blood Cells Mol Dis."},{"key":"2022072115252901800_B27","doi-asserted-by":"crossref","first-page":"730131","DOI":"10.3389\/fonc.2021.730131","article-title":"SARS-CoV-2 infection in cancer patients: a population-based study","volume":"11","author":"Zorzi","year":"2021","journal-title":"Front Oncol."},{"issue":"7","key":"2022072115252901800_B28","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41416-021-01500-z","article-title":"Risk of COVID-19 death in cancer patients: an analysis from Guy\u2019s Cancer Centre and King\u2019s College Hospital in London","volume":"125","author":"Russell","year":"2021","journal-title":"Br J Cancer."},{"issue":"23","key":"2022072115252901800_B29","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1002\/cncr.33160","article-title":"Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19","volume":"126","author":"Cattaneo","year":"2020","journal-title":"Cancer."},{"issue":"9","key":"2022072115252901800_B30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.clml.2021.04.016","article-title":"COVID-19 in 96 patients with hematologic disease: the first single-center experience from the Czech Republic","volume":"21","author":"\u010cer\u0148an","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"12","key":"2022072115252901800_B31","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1172\/JCI141777","article-title":"Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation","volume":"130","author":"Shah","year":"2020","journal-title":"J Clin Invest."},{"issue":"5","key":"2022072115252901800_B32","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1111\/bjh.16935","article-title":"Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King\u2019s College Hospital experience","volume":"190","author":"Shah","year":"2020","journal-title":"Br J Haematol."},{"issue":"2","key":"2022072115252901800_B33","first-page":"1099","article-title":"The outcome of COVID-19 in patients with hematological malignancy","volume":"93","author":"T\u0131\u011fl\u0131o\u011flu","year":"2021"},{"issue":"30","key":"2022072115252901800_B34","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.20.01307","article-title":"Chemotherapy and COVID-19 outcomes in patients with cancer","volume":"38","author":"Jee","year":"2020","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022072115252901800_B35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/10428194.2021.1973671","article-title":"Improvement in mortality of hospitalized patients with hematological malignancies in the 2nd wave of COVID-19 in the UK: experience of a large London NHS trust","volume":"63","author":"Hinton","year":"2021","journal-title":"Leuk Lymphoma."},{"issue":"4","key":"2022072115252901800_B36","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/ejh.13469","article-title":"Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy","volume":"105","author":"Booth","year":"2020","journal-title":"Eur J Haematol."},{"issue":"1","key":"2022072115252901800_B37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ejh.13519","article-title":"SARS-CoV-2 infection among patients with haematological disorders: severity and one-month outcome in 66 Danish patients in a nationwide cohort study","volume":"106","author":"Glenth\u00f8j","year":"2021","journal-title":"Eur J Haematol."},{"issue":"9","key":"2022072115252901800_B38","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1038\/s41375-020-0960-4","article-title":"Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands","volume":"34","author":"van Doesum","year":"2020","journal-title":"Leukemia."},{"issue":"2","key":"2022072115252901800_B39","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/bjh.17027","article-title":"Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy","volume":"191","author":"Fox","year":"2020","journal-title":"Br J Haematol."},{"issue":"7","key":"2022072115252901800_B40","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/2159-8290.CD-20-0516","article-title":"Case fatality rate of cancer patients with COVID-19 in a New York Hospital System","volume":"10","author":"Mehta","year":"2020","journal-title":"Cancer Discov."},{"issue":"7","key":"2022072115252901800_B41","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1080\/10428194.2021.1876865","article-title":"Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort","volume":"62","author":"Bhogal","year":"2021","journal-title":"Leuk Lymphoma."},{"issue":"10","key":"2022072115252901800_B42","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.annonc.2021.07.002","article-title":"Severe COVID-19 in patients with hematological cancers presenting with viremia","volume":"32","author":"Michot","year":"2021","journal-title":"Ann Oncol."},{"key":"2022072115252901800_B43","doi-asserted-by":"crossref","first-page":"100087","DOI":"10.1016\/j.lanepe.2021.100087","article-title":"Evolution of outcomes for patients hospitalised during the first 9 months of the SARS-CoV-2 pandemic in France: a retrospective national surveillance data analysis","volume":"5","author":"Lefrancq","year":"2021","journal-title":"Lancet Reg Health Eur."},{"issue":"18","key":"2022072115252901800_B44","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood.2021011841","article-title":"COVID-19 in patients with CLL: improved survival outcomes and update on management strategies","volume":"138","author":"Roeker","year":"2021","journal-title":"Blood."},{"issue":"5","key":"2022072115252901800_B45","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccell.2020.09.007","article-title":"SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19","volume":"38","author":"Westblade","year":"2020","journal-title":"Cancer Cell."},{"issue":"9","key":"2022072115252901800_B46","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.3201\/eid2709.211159","article-title":"Genomic evolution of SARS-CoV-2 virus in immunocompromised patient, Ireland","volume":"27","author":"Lynch","year":"2021","journal-title":"Emerg Infect Dis."},{"issue":"23","key":"2022072115252901800_B47","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host","volume":"383","author":"Choi","year":"2020","journal-title":"N Engl J Med."},{"issue":"9","key":"2022072115252901800_B48","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/infdis\/jiab075","article-title":"Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection","volume":"223","author":"Tarhini","year":"2021","journal-title":"J Infect Dis."},{"issue":"2","key":"2022072115252901800_B49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ccell.2021.01.001","article-title":"Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients","volume":"39","author":"Abdul-Jawad","year":"2021","journal-title":"Cancer Cell."},{"issue":"5","key":"2022072115252901800_B50","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3324\/haematol.2020.269878","article-title":"Immunologic characterization of COVID-19 patients with hematological cancer","volume":"106","author":"Maia","year":"2020","journal-title":"Haematologica."},{"issue":"1","key":"2022072115252901800_B51","doi-asserted-by":"crossref","first-page":"100943","DOI":"10.1016\/j.tranon.2020.100943","article-title":"Lymphocyte subsets in haematological patients with COVID-19: multicentre prospective study","volume":"14","author":"Kalici\u0144ska","year":"2021","journal-title":"Transl Oncol."},{"issue":"9","key":"2022072115252901800_B52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41408-021-00546-9","article-title":"Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab","volume":"11","author":"Cattaneo","year":"2021","journal-title":"Blood Cancer J."},{"issue":"3","key":"2022072115252901800_B53","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hon.2872","article-title":"Seroconversion and kinetic of anti SARS-COV-2 antibodies in 25 patients with hematological malignancies who recovered from SARS-COV-2 infection","volume":"39","author":"Candoni","year":"2021","journal-title":"Hematol Oncol."},{"issue":"3","key":"2022072115252901800_B54","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bjh.17704","article-title":"COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies","volume":"195","author":"Passamonti","year":"2021","journal-title":"Br J Haematol."},{"issue":"7","key":"2022072115252901800_B55","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1002\/jmv.26886","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion in hematology-oncology patients","volume":"93","author":"Bird","year":"2021","journal-title":"J Med Virol."},{"issue":"8","key":"2022072115252901800_B56","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1158\/2159-8290.CD-21-0191","article-title":"Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in patients with cancer","volume":"11","author":"Bilich","year":"2021","journal-title":"Cancer Discov."},{"key":"2022072115252901800_B57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.03.033","article-title":"Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients","volume":"150","author":"Mansi","year":"2021","journal-title":"Eur J Cancer."},{"issue":"7","key":"2022072115252901800_B58","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med."},{"issue":"27","key":"2022072115252901800_B59","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med."},{"issue":"5","key":"2022072115252901800_B60","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med."},{"issue":"10269","key":"2022072115252901800_B61","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet."},{"issue":"23","key":"2022072115252901800_B62","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med."},{"key":"2022072115252901800_B63","article-title":"Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis","author":"Zheng","year":"2021","journal-title":"Int J Infect Dis."},{"issue":"26","key":"2022072115252901800_B64","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1182\/blood-2011-08-372649","article-title":"Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment","volume":"118","author":"Yri","year":"2011","journal-title":"Blood."},{"issue":"8","key":"2022072115252901800_B65","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell."},{"issue":"8","key":"2022072115252901800_B66","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol."},{"issue":"10","key":"2022072115252901800_B67","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1182\/blood.2021014124","article-title":"COVID-19 in vaccinated adult patients with hematological malignancies. preliminary results from EPICOVIDEHA","volume":"139","author":"Pagano","journal-title":"Blood."},{"issue":"5","key":"2022072115252901800_B68","doi-asserted-by":"crossref","first-page":"100274","DOI":"10.1016\/j.esmoop.2021.100274","article-title":"Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment","volume":"6","author":"Peeters","year":"2021","journal-title":"ESMO Open."},{"issue":"10","key":"2022072115252901800_B69","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ccell.2021.09.001","article-title":"Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell."},{"issue":"8","key":"2022072115252901800_B70","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41408-021-00534-z","article-title":"Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"11","author":"Malard","year":"2021","journal-title":"Blood Cancer J."},{"issue":"9","key":"2022072115252901800_B71","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jtct.2021.06.024","article-title":"Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy: a single-center prospective cohort study","volume":"27","author":"Ram","year":"2021","journal-title":"Transplant Cell Ther."},{"issue":"3","key":"2022072115252901800_B72","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/bjh.17982","article-title":"Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response","volume":"196","author":"Reimann","year":"2021","journal-title":"Br J Haematol."},{"issue":"3","key":"2022072115252901800_B73","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/bloodadvances.2021006101","article-title":"Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"6","author":"Jim\u00e9nez","year":"2022","journal-title":"Blood Adv."},{"issue":"1","key":"2022072115252901800_B74","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/07357907.2021.1992420","article-title":"Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy","volume":"40","author":"Ariamanesh","year":"2022","journal-title":"Cancer Invest."},{"issue":"11","key":"2022072115252901800_B75","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1001\/jamaoncol.2021.4381","article-title":"Antibody response to COVID-19 vaccination in adults with hematologic malignant disease","volume":"7","author":"Ollila","year":"2021","journal-title":"JAMA Oncol."},{"issue":"2","key":"2022072115252901800_B76","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-021-00746-4","article-title":"Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine","volume":"22","author":"Gavriatopoulou","journal-title":"Clin Exp Med."},{"issue":"13","key":"2022072115252901800_B77","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1080\/10428194.2021.1957877","article-title":"Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies","volume":"62","author":"Re","year":"2021","journal-title":"Leuk Lymphoma."},{"issue":"10","key":"2022072115252901800_B78","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Herzog Tzarfati","year":"2021","journal-title":"Am J Hematol."},{"key":"2022072115252901800_B79","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s43018-021-00275-9","article-title":"Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study","volume":"2","author":"Fendler","year":"2021","journal-title":"Nat Cancer."},{"issue":"1","key":"2022072115252901800_B80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ccell.2021.11.006","article-title":"Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer","volume":"40","author":"Shapiro","journal-title":"Cancer Cell."},{"key":"2022072115252901800_B81","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280026","article-title":"A third anti-SARS-Cov2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and\/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia [published online ahead of print]","author":"Kohn","year":"2021","journal-title":"Haematologica."},{"issue":"8","key":"2022072115252901800_B82","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell."},{"issue":"4","key":"2022072115252901800_B83","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bjh.17743","article-title":"Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients","volume":"195","author":"Benda","year":"2021","journal-title":"Br J Haematol."},{"issue":"12","key":"2022072115252901800_B84","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41408-021-00594-1","article-title":"Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies","volume":"11","author":"Tamariz-Amador","year":"2021","journal-title":"Blood Cancer J."},{"issue":"17","key":"2022072115252901800_B85","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.3390\/cancers13174480","article-title":"Poor neutralizing antibody responses in 132 patients with CLL, NHL and HL after vaccination against SARS-CoV-2: a prospective study","volume":"13","author":"Terpos","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"23","key":"2022072115252901800_B86","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N Engl J Med."},{"issue":"6","key":"2022072115252901800_B87","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cell.2022.01.029","article-title":"T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals","volume":"185","author":"Naranbhai","year":"2022","journal-title":"Cell."},{"issue":"2","key":"2022072115252901800_B88","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S2213-2600(22)00010-8","article-title":"Fourth dose of COVID-19 vaccines in Israel","volume":"10","author":"Burki","year":"2022","journal-title":"Lancet Respir Med."},{"issue":"12","key":"2022072115252901800_B89","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1097\/TP.0000000000003934","article-title":"Antibody response to a fourth dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: a case series","volume":"105","author":"Alejo","year":"2021","journal-title":"Transplantation."},{"issue":"3","key":"2022072115252901800_B90","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41422-022-00618-w","article-title":"SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination","volume":"32","author":"Li","year":"2022","journal-title":"Cell Res."},{"issue":"10","key":"2022072115252901800_B91","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMc2119407","article-title":"Efficacy of antibodies and antiviral drugs against Covid-19 Omicron variant","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med."},{"key":"2022072115252901800_B92","doi-asserted-by":"crossref","first-page":"105252","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antiviral Res."},{"issue":"6575","key":"2022072115252901800_B93","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science."},{"issue":"15","key":"2022072115252901800_B94","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med."},{"issue":"19","key":"2022072115252901800_B95","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19: final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med."},{"issue":"4","key":"2022072115252901800_B96","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med."},{"issue":"9","key":"2022072115252901800_B97","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat Struct Mol Biol."},{"issue":"6","key":"2022072115252901800_B98","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","journal-title":"N Engl J Med."},{"issue":"6","key":"2022072115252901800_B99","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood.2020006964","article-title":"Use of convalescent plasma in hospitalized patients with COVID-19: case series","volume":"136","author":"Hegerova","year":"2020","journal-title":"Blood."},{"issue":"1","key":"2022072115252901800_B100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/infdis\/jiaa228","article-title":"Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019","volume":"222","author":"Zeng","year":"2020","journal-title":"J Infect Dis."},{"issue":"13","key":"2022072115252901800_B101","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent Covid-19","volume":"385","author":"O\u2019Brien","year":"2021","journal-title":"N Engl J Med."},{"issue":"1","key":"2022072115252901800_B102","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiaa666","article-title":"Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient","volume":"223","author":"Baang","year":"2021","journal-title":"J Infect Dis."},{"issue":"3","key":"2022072115252901800_B103","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3390\/v13030436","article-title":"Early administration of convalescent plasma improves survival in patients with hematological malignancies and COVID-19","volume":"13","author":"Biernat","year":"2021","journal-title":"Viruses."},{"issue":"5","key":"2022072115252901800_B104","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hon.2908","article-title":"Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients","volume":"39","author":"Weinbergerova","year":"2021","journal-title":"Hematol Oncol."},{"issue":"20","key":"2022072115252901800_B105","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood."},{"issue":"3","key":"2022072115252901800_B106","doi-asserted-by":"crossref","first-page":"103075","DOI":"10.1016\/j.transci.2021.103075","article-title":"Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies","volume":"60","author":"Jeyaraman","year":"2021","journal-title":"Transfus Apheresis Sci."},{"key":"2022072115252901800_B107","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijid.2020.12.050","article-title":"Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir","volume":"104","author":"Camprub\u00ed","year":"2021","journal-title":"Int J Infect Dis."},{"issue":"3","key":"2022072115252901800_B108","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2991\/chi.k.210403.001","article-title":"Therapeutic use of convalescent plasma in COVID-19 infected patients with concomitant hematological disorders","volume":"3","author":"Lanza","year":"2021","journal-title":"Clin Hematol Int."},{"issue":"22","key":"2022072115252901800_B109","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1002\/cam4.3457","article-title":"Convalescent plasma for the treatment of severe COVID-19 infection in cancer patients","volume":"9","author":"Tremblay","year":"2020","journal-title":"Cancer Med."},{"issue":"8","key":"2022072115252901800_B110","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med."},{"issue":"3","key":"2022072115252901800_B111","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-021-01678-y","article-title":"An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies","volume":"28","author":"VanBlargan","year":"2022","journal-title":"Nat Med."},{"issue":"7906","key":"2022072115252901800_B112","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature."},{"issue":"7857","key":"2022072115252901800_B113","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature."},{"issue":"21","key":"2022072115252901800_B114","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med."},{"issue":"2860","key":"2022072115252901800_B115","doi-asserted-by":"crossref","first-page":"n2860","DOI":"10.1136\/bmj.n2860","article-title":"Covid-19: AstraZeneca says its antibody drug AZD7442 is effective for preventing and reducing severe illness","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ."},{"issue":"4","key":"2022072115252901800_B116","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jama.2021.24931","article-title":"Tixagevimab and cilgavimab (evusheld) for pre-exposure prophylaxis of COVID-19","volume":"327","author":"Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19","year":"2022","journal-title":"JAMA."},{"issue":"1646","key":"2022072115252901800_B117","first-page":"47","article-title":"COVID-19 updates: booster immunization in persons who are immunocompromised","volume":"64","year":"2022","journal-title":"Med Lett Drugs Ther."},{"issue":"14","key":"2022072115252901800_B118","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa2119658","article-title":"Population immunity and Covid-19 severity with Omicron variant in South Africa","volume":"386","author":"Madhi","year":"2022","journal-title":"N Engl J Med."},{"key":"2022072115252901800_B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016147","article-title":"Patients with CLL have lower risk of death from COVID-19 in the omicron era [published online ahead of print 19 May 2022]","volume-title":"Blood","author":"Niemann"},{"issue":"12","key":"2022072115252901800_B120","doi-asserted-by":"crossref","first-page":"7591","DOI":"10.1007\/s00520-021-06324-4","article-title":"The impact of COVID-19 on patients with hematological malignancies: the mixed-method analysis of an Israeli national survey","volume":"29","author":"Levy","year":"2021","journal-title":"Support Care Cancer."},{"issue":"12","key":"2022072115252901800_B121","doi-asserted-by":"crossref","first-page":"7755","DOI":"10.1007\/s00520-021-06369-5","article-title":"Prevalence and correlates of psychological distress, unmet supportive care needs, and fear of cancer recurrence among haematological cancer patients during the COVID-19 pandemic","volume":"29","author":"Zomerdijk","year":"2021","journal-title":"Support Care Cancer."},{"key":"2022072115252901800_B122","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3389\/fonc.2020.01270","article-title":"psychological distress in outpatients with lymphoma during the COVID-19 pandemic","volume":"10","author":"Romito","year":"2020","journal-title":"Front Oncol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/3\/236\/1909152\/bloodbld2021012251c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/3\/236\/1909152\/bloodbld2021012251c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T15:27:30Z","timestamp":1658417250000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/3\/236\/485212\/COVID-19-in-patients-with-hematologic-malignancy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":122,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021012251","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]}}}